Llwytho...
Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
INTRODUCTION: Ubrogepant is an oral, small-molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of migraine. The efficacy and safety of ubrogepant were demonstrated in two pivotal phase 3, single-attack, randomized, placebo-controlled trials (ACHIEVE I and AC...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Neurol Ther |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Springer Healthcare
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8140011/ https://ncbi.nlm.nih.gov/pubmed/33608814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-021-00234-7 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|